WhiteLab Genomics has secured $26 million in Series B funding to advance its AI-driven approach to gene therapy delivery. The company aims to overcome the challenge of ensuring genetic treatments reach the correct cells, a critical step for efficacy. Early research with the Paris Brain Institute has demonstrated promising results in mice for delivering therapies to difficult-to-access areas, including the brain. AI
IMPACT This funding could accelerate the development of AI-driven solutions for targeted drug delivery, potentially improving the efficacy of gene therapies.
RANK_REASON Significant funding round for a company using AI in a novel application within the life sciences sector. [lever_c_demoted from significant: ic=1 ai=0.7]
Read on Mastodon — mastodon.social →
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →